Efficacy and safety of Suhuang cough capsule in the adjuvant treatment of cough variant asthma
苏黄止咳胶囊辅助治疗咳嗽变异性哮喘的疗效及安全性

摘要

目的 分析苏黄止咳胶囊用于咳嗽变异性哮喘的价值。方法 对2020年9月-2022年8月本科接诊咳嗽变异性哮喘病人（n=72）进行随机分组，试验和对照组各36人，前者用苏黄止咳胶囊，后者行常规治疗。对比气喘消失时间等指标。结果 关于咳嗽缓解时间和气喘消失时间，试验组数据分别是（7.31±2.56）d、（3.39±0.92）d，和对照组数据（11.57±1.54）d、（6.68±0.79）d相比更短（P＜0.05）。关于总有效率这个指标：试验组数据97.22%，和对照组数据80.56%相比更高（P＜0.05）。关于FVC和FEV1，治疗结束时：试验组数据分别是（3.91±0.52）L、（3.05±0.37）L，和对照组数据（2.71±0.41）L、（3.01±0.42）L相比更高（P＜0.05）。关于不良反应，试验组发生率5.56%，和对照组数据22.22%相比更低（P＜0.05）。关于sf-36评分，治疗结束时：试验组数据（87.25±3.69）分，和对照组数据（80.34±4.17）分相比更高（P＜0.05）。结论 咳嗽变异性哮喘用苏黄止咳胶囊，不良反应发生率更低，预后更好，症状缓解更为迅速，疗效提升更加明显，肺功能改善也更为迅速。

Abstract

Objective To analyze the value of Suhuang cough capsule for cough variant asthma.
Methods Cough variant asthma patients (n=72) from September 2020 to August 2022 were randomized, with 36 people each in the control group, the former with Suhuang cough capsules and the latter with conventional treatment. Compare the disappearance time of wheezing and other indicators.
Results For cough relief time and asthma disappearance time, the test group data were (7.31 ± 2.56) d, (3.39 ± 0.92) d, and the control group data (11.57 ± 1.54) d, (6.68 ± 0.79) d were shorter (P <0.05). On the total response efficiency index: 97.22%, higher than 80.56% in the control group (P <0.05). For FVC and FEV1, at the end of treatment: trial group data were (3.91 ± 0.52) L, (3.05 ± 0.37) L, and control group data (2.71 ± 0.41) L, (3.01 ± 0.42) L were higher (P <0.05). Regarding the adverse reactions, the incidence rate was 5.56%, which was lower compared with the 22.22% data in the control group (P <0.05). For the sf-36 score, at the end of treatment: the trial group data (87.25 ± 3.69) and the control group data (80.34 ± 4.17) scores were higher (P <0.05).
Conclusion   Suhuang cough capsule for cough variant asthma has a lower incidence of adverse reactions, better prognosis, faster symptom relief, more obvious improvement of efficacy, and faster improvement of lung function.